title: Pharma industry in India.
abstract: Globally ranked fourth by volume and 13th in value, the Indian pharma industry is a leading producer of high-quality, low-cost generic drugs. Its 14% share of the USD 57 billion world generic market is expected to increase to 50% by 2010. With the advantages of cost competitiveness, ability and experience in reverse engineering, availability of skilled scientific and engineering personnel and the capability to produce raw materials for a wide range of drugs from the basic stage, the industry delivers the entire range of therapeutic products. McKinsey & Co. predict that India's pharmaceutical market could reach a size of USD 20 billion by 2015, becoming one of the top 10 drug markets in the world. Generic versions of the cardiovascular drug carvedilol, ANDA-approved allopurinol, verapamil SR and the anticancer drug paclitaxel are some of the recent products introduced by Indian companies, with Caraco, Ranbaxy, Dabur, Dr. Reddy's, Nicholas Piramal India, leading the list. Setting up of integrated drug development companies and aggressive entries into the Japanese drug market have provided further impetus to the country's pharma manufacturing arena.
authors.affiliation: Domex Business Information Pvt Ltd, Chennai, India.
authors.forename: V M
authors.initials: VM
authors.lastname: Sundaram
mesh_terms: D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000639:trends*; D016568:Drugs, Generic; D007194:India; D007564:Japan; D010330:Patents as Topic; D012106:Research
chemical_list: D016568:Drugs, Generic